Department of Chemistry, Washington State University, Pullman, WA 99164, USA.
Int J Oncol. 2014 Mar;44(3):918-22. doi: 10.3892/ijo.2014.2256. Epub 2014 Jan 10.
Developing simple and effective approaches to detect tumor markers will be critical for early diagnosis or prognostic evaluation of prostate cancer treatment. Prostate‑specific membrane antigen (PSMA) has been validated as an important tumor marker for prostate cancer progression including angiogenesis and metastasis. As a type II membrane protein, PSMA can be constitutively internalized from the cell surface into endosomes. Early endosomes can fuse with multivesicular bodies (MVB) to form and secrete exosomes (40-100 nm) into the extracellular environment. Herein, we tested whether some of the endosomal PSMA could be transferred to exosomes as an extracellular resource for PSMA. Using PSMA-positive LNCaP cells, the secreted exosomes were collected and isolated from the cultured media. The vesicular structures of exosomes were identified by electron microscopy, and exosomal marker protein CD9 and tumor susceptibility gene (TSG 101) were confirmed by western blot analysis. Our present data demonstrate that PSMA can be enriched in exosomes, exhibiting a higher content of glycosylation and partial proteolysis in comparison to cellular PSMA. An in vitro enzyme assay further confirmed that exosomal PSMA retains functional enzymatic activity. Therefore, our data may suggest a new role for PSMA in prostate cancer progression, and provide opportunities for developing non-invasive approaches for diagnosis or prognosis of prostate cancer.
开发简单有效的肿瘤标志物检测方法对于前列腺癌治疗的早期诊断或预后评估至关重要。前列腺特异性膜抗原(PSMA)已被验证为前列腺癌进展的重要肿瘤标志物,包括血管生成和转移。作为一种 II 型膜蛋白,PSMA 可以从细胞表面持续内化到内体中。早期内体可以与多泡体(MVB)融合,形成并将外泌体(40-100nm)分泌到细胞外环境中。在此,我们测试了部分内体 PSMA 是否可以作为 PSMA 的细胞外资源转移到外泌体中。使用 PSMA 阳性的 LNCaP 细胞,从培养的培养基中收集和分离分泌的外泌体。通过电子显微镜鉴定外泌体的囊泡结构,并通过 Western blot 分析证实外泌体标记蛋白 CD9 和肿瘤易感性基因(TSG101)。我们目前的数据表明 PSMA 可以在外泌体中富集,与细胞 PSMA 相比,其糖基化和部分蛋白水解程度更高。体外酶测定进一步证实外泌体 PSMA 保留了功能性酶活性。因此,我们的数据可能提示 PSMA 在前列腺癌进展中发挥新的作用,并为开发用于前列腺癌诊断或预后的非侵入性方法提供机会。